BioDelivery Sciences International completed the refinancing of its existing debt agreement with a new facility from BioPharma Credit consisting of a $60 million term loan. The refinancing will generate an estimated $1.5 million in annual interest cost savings compared to the previous debt facility.
“We are pleased to announce this debt re-financing with BPCR, an investment fund managed by Pharmakon Advisors, a leading financing partner in the healthcare space,” commented Terry Coelho, CFO for BDSI. “Following our recent equity raise of $50 million, this new and lower cost debt facility further strengthens our balance sheet and provides BDSI with added flexibility to continue to drive the transformation of BDSI into a successful commercial-stage specialty pharmaceutical company. Additionally, this new facility is cash flow accretive, extends our debt maturity and lowers our overall cost of capital.”
The new facility carries a 72-month term with interest only payments for the first 36 months. The interest rate on the term loan is 7.5% plus the LIBOR rate, which at the closing resulted in a rate of 10.0%. An additional feature of the new facility is the flexibility to draw an additional $20.0 million within the first 12 months of the agreement. BDSI will have a total debt balance of $60 million after closing.
Proceeds from this financing, along with available cash on hand, were used to repay and retire the company’s existing term loan with CRG Servicing, which had an outstanding balance of $61.8 million, an interest rate of 12.5% as well as a back-end facility fee, and a maturity date of December 2022.
BioDelivery Sciences International is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
